Drug Combination Details
| General Information of the Combination (ID: C98556) | |||||
|---|---|---|---|---|---|
| Name | Visnagin NP Info | + | Doxorubicin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Cardiomyopathy
[ICD-11: BC43]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Decreasing Adverse Drug Reaction by This Combination | ||||||
| Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | MDH2 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | DU145 | CVCL_0105 | Prostate carcinoma | Homo sapiens | ||
| LNCaP | CVCL_0395 | Prostate carcinoma | Homo sapiens | |||
| MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | |||
| MDA-MB-231 | CVCL_0062 | Breast adenocarcinoma | Homo sapiens | |||
| In-vivo Model | Zebrafish and male C57BL/6 mice were used in this study. | |||||
| Experimental
Result(s) |
Visnagin protects against doxorubicin-induced cardiomyopathy through modulation of mitochondrial malate dehydrogenase. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Visnagin protects against doxorubicin-induced cardiomyopathy through modulation of mitochondrial malate dehydrogenase. Sci Transl Med. 2014 Dec 10;6(266):266ra170. | |||
